ABL receives new patent for TherapyEdge and ViroScore technology

Sep 21 2010

Advanced Biological Laboratories (ABL) S.A., a biomedical company engaged in the development and commercialization of personalized healthcare electronic medical record systems coupled with expert rules using decision support tools, is pleased to announce today that the Canadian Intellectual Property Office has issued a Notice of Allowance and the Patent Office of India has issued a new patent for our patent applications derived from our U.S. Patent Nos. 6,081,786 and 6,188,988 to Barry et al.

“We are very pleased with this positive news, confirming the innovative value of our patent estate, and reinforcing the patentability of the '786 and '988 patents”

In the United States, the '786 and '988 patents each have been challenged by four separate patent reexamination requests, which have all been denied or had prosecution closed. In each case, the U.S. Patent and Trademark Office affirmed the patentability of Claims 1-66 of each patent without amendment, and reexamination certificates have been issued or are pending for each patent.

"We are very pleased with this positive news, confirming the innovative value of our patent estate, and reinforcing the patentability of the '786 and '988 patents," said Dr. Chalom Sayada, CEO of ABL. "This news will allow us to continue to develop our commercial activities in the U.S., Canada, and India with our proprietary technology, TherapyEdge™ and ViroScore™. They further reinforce our decision to support all research and not-for-profit activities, while providing potential patent licensing opportunities for those with commercial products in the personalized healthcare business."

ABL has actively engaged with academics and researchers to teach them more about ABL's patents and its willingness to collaborate with the scientific and nonprofit community by providing unrestricted access to ABL's patents, both in the U.S. and in developing countries.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented for the past several years," continued Dr Sayada. "The issuance of these patents and the affirmation of the U.S. patents will be very important to further expanding our worldwide patent protection and business development for our TherapyEdge™ platform with strategic corporate and industrial partners."